基于基托和L.Eclipta prostrata的生物材料的静血能力的评估. 提取物 提取物提取物
Nguyen Ngoc Linh1, Vu Quoc Manh1, La Chau Giang2
1Faculty of Pharmacy, Thanh Do University, Kim Chung, Hoai Duc, Hanoi 10000, Vietnam.
Biomedical materials (Bristol, England)
|March 27, 2024
概括
新的奇托桑和Eclipta prostrata生物材料显示出出色的止血特性. 使用微乳液或三聚酸盐 (STPP) 溶液方法制备的这些材料表现出快速的血液凝结和聚合,表明了潜在的生物医学应用.
科学领域:
- 生物材料科学 生物材料科学
- 聚合物化学 聚合物化学
- 自然产品化学 自然产品化学
背景情况:
- 奇托是一种具有血静潜力的生物相容多糖.
- 埃克利普塔 prostrata L. 提取物含有黄酸盐,以其药用特性而闻名.
- 开发有效的静血剂对于生物医学应用至关重要.
研究的目的:
- 为了合成和表征奇托桑/Eclipta prostrata L.提取生物材料.
- 评估这些新型生物材料的静血疗效.
- 为了比较不同的制备方法 (微乳液与溶液) 和三聚酸 (STPP) 交叉链接的影响.
主要方法:
- 通过微乳液和溶液方法合成生物材料.
- 三聚酸盐 (STPP) 用作交叉链接剂.
- 使用红外光谱学,动态光散射和场辐射扫描电子显微镜进行表征.
- 通过血液凝结时间和球聚合试验进行静血评估.
主要成果:
- 通过红外光谱学 (C-O-P键振动在1152厘米−1) 确认了奇托与STPP的成功交叉链接.
- 颗粒大小在68.06nm至1484nm之间,微乳液方法产生更小的颗粒.
- 与对照组相比,生物材料表现出优越的静血能力,其中1:30的提取物:基托桑比率显示出最快的凝血 (6分46秒) 和最低的聚合 (13.05%在5分钟).
结论:
- 基托桑和Eclipta prostrata L. 提取物生物材料使用微乳液和溶液方法有效地制备.
- STPP交叉链接可以增强生物材料的特性.
- 这些新型生物材料显示出显著的静血潜力,使它们成为生物医学应用的有希望的候选者.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
690
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
690
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.5K